FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      JonesResearch Begins Coverage of AbCellera Biologics with Buy Rating

      JonesResearch has initiated coverage of AbCellera Biologics Inc. (NASDAQ:ABCL), assigning the company a Buy rating and establishing a price target of $11. This assessment highlights the firm's belief in the significant growth potential of AbCellera's stock, which is currently priced under $5.

      AbCellera is recognized for its validated antibody discovery platform, which has successfully advanced 19 molecules into clinical trials. This achievement underscores the company's capabilities in biopharmaceutical development and positions it favorably within the biotechnology sector.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud